Iovance Biotherapeutics, Inc.

XNASHealth care

Last traded price · USD

$8.61

−1.08%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:06 IST · A quote does not mean the product is available to trade on your account.

Day's open: $8.40
Previous close: $8.70
Volume: 2.4M
Day's high: $8.70
Day's low: $8.11

In brief

Iovance Biotherapeutics, Inc. is a health care company listed on Nasdaq, valued at about $3.90B.
Its shares closed at $8.70 on 4 Nov 2026, up 378.0% over the past year.
From India you can buy IOVA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Iovance Biotherapeutics, Inc. (IOVA) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IOVA share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IOVA options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −32.9% (SPY −1.6%, XLV +13.5%). 3 months: +100.5% (SPY −0.4%, XLV +15.5%). 1 year: +378.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IOVA, SPY and XLV · as of 4 Nov 2026
Volume 3.8× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 59.2M shares was 3.8× the average of the 30 sessions before it (15.7M), as the price fell 35.4%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Short interest at 13.0% of shares outstanding
58.9M shares were sold short at the 15 Oct 2026 settlement, 13.0% of the 453.0M shares outstanding; covering them would take 4.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $8.70 was 23.6% below its 50-day average ($11.39) and 46.7% above its 200-day average ($5.93). It has closed above the 200-day for 201 sessions, since 20 Jan 2026. The 50-day average crossed above the 200-day on 14 Jan 2026, 203 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
50% of the way up its 52-week range
Closed at $8.70 on 4 Nov 2026: 43.4% below the 52-week high of $15.37 (21 Oct 2026) and 318.3% above the low of $2.08 (16 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−32.9%

6 months+112.7%

1 year+378.0%

5 years−64.5%

Newswire

About

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Website

Notable moves

August 6, 2026
+43.09%
May 9, 2025
−44.79%
May 27, 2022
−53.57%

Newswire

About

Website

Notable moves

August 6, 2026
+43.09%
May 9, 2025
−44.79%
May 27, 2022
−53.57%

Iovance Biotherapeutics, Inc.

XNASHealth care

Last traded price · USD

$8.61

−1.08%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:06 IST · A quote does not mean the product is available to trade on your account.

Day's open: $8.40
Previous close: $8.70
Volume: 2.4M
Day's high: $8.70
Day's low: $8.11

In brief

Iovance Biotherapeutics, Inc. is a health care company listed on Nasdaq, valued at about $3.90B.
Its shares closed at $8.70 on 4 Nov 2026, up 378.0% over the past year.
From India you can buy IOVA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Iovance Biotherapeutics, Inc. (IOVA) shares from India?

Do I need the price of a whole IOVA share to invest?

How much can I invest in US stocks in a year?

Can I trade IOVA options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −32.9% (SPY −1.6%, XLV +13.5%). 3 months: +100.5% (SPY −0.4%, XLV +15.5%). 1 year: +378.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IOVA, SPY and XLV · as of 4 Nov 2026
Volume 3.8× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 59.2M shares was 3.8× the average of the 30 sessions before it (15.7M), as the price fell 35.4%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Short interest at 13.0% of shares outstanding
58.9M shares were sold short at the 15 Oct 2026 settlement, 13.0% of the 453.0M shares outstanding; covering them would take 4.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $8.70 was 23.6% below its 50-day average ($11.39) and 46.7% above its 200-day average ($5.93). It has closed above the 200-day for 201 sessions, since 20 Jan 2026. The 50-day average crossed above the 200-day on 14 Jan 2026, 203 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
50% of the way up its 52-week range
Closed at $8.70 on 4 Nov 2026: 43.4% below the 52-week high of $15.37 (21 Oct 2026) and 318.3% above the low of $2.08 (16 Dec 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−32.9%

6 months+112.7%

1 year+378.0%

5 years−64.5%

Newswire

About

Website

Notable moves

August 6, 2026
+43.09%
May 9, 2025
−44.79%
May 27, 2022
−53.57%

Newswire

About

Website

Notable moves

August 6, 2026
+43.09%
May 9, 2025
−44.79%
May 27, 2022
−53.57%

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Volume 3.8× its 30-session average on 29 Oct 2026

Short interest at 13.0% of shares outstanding

Below its 50-day average, above its 200-day

50% of the way up its 52-week range

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Volume 3.8× its 30-session average on 29 Oct 2026

Short interest at 13.0% of shares outstanding

Below its 50-day average, above its 200-day

50% of the way up its 52-week range